A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.

Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources

Rethinking Early Detection: How RACOON-MARDER Aims to Spot Liver Cancer Sooner
Hepatocellular carcinoma (HCC) is often diagnosed too late, limiting treatment options and survival. The RACOON-MARDER project aims to change that. By…

Structured Reporting and AI in Radiology: Efficiency and Quality in Prostate Diagnostics
How are structured reporting and artificial intelligence transforming radiology practice? Prof. Dr. Thorsten Persigehl from University Hospital…

Rare Tumors, Big Goals: How RACOON-SAGA Aims to Improve Therapy Decisions
Rare tumors, major challenges: The RACOON-SAGA project explores how imaging and clinical data can improve the pre-therapeutic characterization of soft…